61 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
its safety, efficacy and the patent or other proprietary position.
“Competent Authority” means any local or national agency, court, authority … with the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the Licensed Product, and is consistent with 21 CFR
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of Risk Factors
Risks Related to Tenet
There may be substantial delays in future clinical trials of TNT119 or TNT119 may fail to demonstrate safety … may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.
Before obtaining marketing approval from
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
absorption, distribution, metabolism and excretion of any product with the object of ascertaining its safety and/or efficacy
1.4
“Commercial Product License … indications for such compound, product or technology, or any discovery or development that improves the stability, safety or efficacy of such compound, product
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of a product of similar commercial potential at a similar stage in its development or lifecycle, in each case taking into account issues of safety … all biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, safety, quality control, preclinical and clinical
8-K
s9u3a fx7431lprp4v8
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
6mm9fvtys1h
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
DEFM14A
j6itvl4w8gt g9qsnz
4 Jun 24
Proxy related to merger
8:00am
PREM14A
1tfm0p v8
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
layw6n238eovhrinvd
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
j0awyidw2mkqj ht
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.3
2x0i4kfb6zhhm
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
c1j92y3jf xb28
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
wazu1f2z
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.1
lwzgpn
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
xyv9qx80 hflt1mtgie
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am